Pharmacia & Upjohn acquires Glyset oral antidiabetic Rx, OTC rights from Bayer.
This article was originally published in The Tan Sheet
Executive Summary
GLYSET ORAL ANTIDIABETIC OTC RIGHTS TO P&U under an agreement with Bayer to acquire marketing rights to Rx miglitol in the U.S., Canada, Australia and New Zealand, Pharmacia & Upjohn announced Aug. 31. In addition to rights to sell Glyset as a prescription treatment for Type II diabetes, the deal "provides P&U with rights to market Glyset for over-the-counter use in the future," the company said. This stipulation applies to all markets covered by the agreement.